Site menu

Search by ticker code:
Generic filters


Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Resmed (ASX:RMD) boosts profit 12% – is now the time to buy shares?

Homegrown medical device company Resmed Inc (ASX: RMD) has updated the market with its second-quarter results, boosting profit 12% year on year.

The market has largely unreacted to today’s update, with the Resmed share price up just 0.70% to $31.18.

Resmed provides new solutions and technologies to treat sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases.

Philips recall spurs demand

Key financial results from the second quarter ending 31 December include:

  • Revenue of $894.9 million, a 12% increase year-on-year (YoY)
  • Gross margin of 56.4%, a decrease of 140 basis points (1.4%) YoY
  • Net income of $201.8 million, an increase of 12% YoY
  • Diluted earnings per share of $1.37

The demand for Resmed’s product remains elevated after competitor Philips issued a recall during 2021.

“We are working every day to meet the extraordinary demand generated by our competitor’s ongoing device recall”

It was an even contribution geographically, with revenue increasing 14% in the Americas and 12% in Europe, Asia and other markets.

From a division lens, new devices sold increased 15% over the quarter. Masks and other consumables grew 9%.

Meanwhile, software-as-a-service revenue increased 9%.

Costs weigh on margins

Management called out elevated freight and manufacturing costs impacting gross profit.

This was somewhat offset by a demand shift to higher-margin products.

“Our global ResMed team continues to find ways to deliver products and solutions to our customers, even amid ongoing supply chain challenges that have limited additional access to critical electronic components”

The gross profit was also offset by relatively lower selling, general and administrative (SGA) expenses.

SGA increased 10%, slower than the 12% revenue growth.

Is now the time to buy Resmed shares?

Resmed reports in US dollars and is also listed in the United States.

Annualising this quarter’s earnings per share of $1.37 gives $6.65 of earnings for the year.

Using its US share price of ~$225, the company is trading on an earnings multiple of approximately 34.

It’s by no means cheap, especially given the low to mid-teens annual growth rate.

But for a long-term investor, with a diversified portfolio, Resmed is a solid core holding.

I personally wouldn’t buy shares (I’m a cheapskate), as there are other companies I’d rather own.

If you’re looking for new share ideas, check out four ASX shares I’m watching in 2022

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Lachlan does not have a financial or commercial interest in any of the companies or funds mentioned.
Skip to content